• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Fluidigm Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FLDM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FLDM

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Fluidigm in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for FLDM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Fluidigm. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2021Piper SandlerLower TargetOverweight$8.00 ➝ $7.00Medium
2/11/2021Piper SandlerLower Target$15.00 ➝ $8.00Low
8/27/2020UBS GroupBoost TargetBuy$12.00 ➝ $16.00High
8/10/2020UBS GroupBoost TargetBuy$6.00 ➝ $12.00Low
8/7/2020Piper SandlerBoost TargetOverweight$9.00 ➝ $12.00Medium
7/9/2020Piper SandlerReiterated RatingOverweight ➝ Market Perform$9.00High
7/9/2020BTIG ResearchReiterated RatingBuy$12.00High
2/11/2020Piper SandlerLower Target$14.00 ➝ $9.00High
11/6/2019Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
10/18/2019UBS GroupUpgradeNeutral ➝ Buy$14.00 ➝ $7.00High
5/3/2019Piper Jaffray CompaniesBoost TargetIn-Line ➝ Overweight$14.00 ➝ $16.00High
3/15/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$14.00High
3/13/2019BTIG ResearchInitiated CoverageBuy$15.00High
3/13/2019Piper Jaffray CompaniesBoost TargetOverweight$10.00 ➝ $14.00High
1/3/2019Janney Montgomery ScottUpgradeNeutral ➝ BuyLow
11/2/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightLow
2/8/2018Piper Jaffray CompaniesReiterated RatingHold$6.10High
(Data available from 11/28/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/31/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/30/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/29/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Fluidigm logo
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $3.66
Low: $3.27
High: $3.99

52 Week Range

Now: N/A

Volume

60,126 shs

Average Volume

968,838 shs

Market Capitalization

$283.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Fluidigm?

The following Wall Street sell-side analysts have issued reports on Fluidigm in the last year: StockNews.com.
View the latest analyst ratings for FLDM.

What is the current price target for Fluidigm?

0 Wall Street analysts have set twelve-month price targets for Fluidigm in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Fluidigm in the next year.
View the latest price targets for FLDM.

What is the current consensus analyst rating for Fluidigm?

Fluidigm currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FLDM.

What other companies compete with Fluidigm?

How do I contact Fluidigm's investor relations team?

Fluidigm's physical mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The medical research company's listed phone number is (650) 266-6000 and its investor relations email address is [email protected] The official website for Fluidigm is www.fluidigm.com. Learn More about contacing Fluidigm investor relations.